NCT05201781 A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
| NCT ID | NCT05201781 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Janssen Research & Development, LLC |
| Condition | Multiple Myeloma |
| Study Type | INTERVENTIONAL |
| Enrollment | 295 participants |
| Start Date | 2022-03-09 |
| Primary Completion | 2037-07-29 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 295 participants in total. It began in 2022-03-09 with a primary completion date of 2037-07-29.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.
Eligibility Criteria
Inclusion Criteria: * Participants who have received at least one dose of cilta-cel in a Company-sponsored clinical study * Participants who have provided informed consent for this study
Contact & Investigator
Janssen Research & Development, LLC Clinical Trial
STUDY DIRECTOR
Janssen Research & Development, LLC
Frequently Asked Questions
Who can join the NCT05201781 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Multiple Myeloma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05201781 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT05201781 currently recruiting?
Yes, NCT05201781 is actively recruiting participants. Contact the research team at Participate-In-This-Study1@its.jnj.com for enrollment information.
Where is the NCT05201781 trial being conducted?
This trial is being conducted at Phoenix, United States, Duarte, United States, San Francisco, United States, Stanford, United States and 11 additional locations.
Who is sponsoring the NCT05201781 clinical trial?
NCT05201781 is sponsored by Janssen Research & Development, LLC. The principal investigator is Janssen Research & Development, LLC Clinical Trial at Janssen Research & Development, LLC. The trial plans to enroll 295 participants.